查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2018668

miRNA定序与检测市场：2026-2032年全球市场预测（按产品类型、技术、工作流程、样本类型、应用和最终用户划分）

miRNA Sequencing & Assay Market by Product Type, Technology, Workflow, Sample Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，miRNA定序和检测市场价值将达到 4.3569 亿美元，到 2026 年将成长到 5.0241 亿美元，到 2032 年将达到 11.2765 亿美元，年复合成长率为 14.55%。

主要市场统计数据
基准年 2025 4.3569亿美元
预计年份：2026年 5.0241亿美元
预测年份 2032 11.2765亿美元
复合年增长率 (%) 14.55%

全面概述现代 miRNA定序和检测技术，重点介绍其科学潜力和转化为临床应用所面临的挑战。

微型RNA定序和检测技术已迅速从一项小众研究技术发展成为转化研究和临床开发中分子谱分析策略的核心要素。样本製备、样品製备化学和分析流程的进步提高了小RNA检测的可靠性，同时仪器设备的改进也缩短了检测週期，降低了常规应用门槛。因此，学术机构、受託研究机构、医院和诊断检查室以及製药和生物技术公司的相关人员现在不仅将微小RNA解决方案视为探索性工具，而且将其视为生物标记开发、伴随诊断和标靶治疗发现的候选方案。

一项关键的变革重塑了 miRNA定序和检测工作流程，实现了可扩展的临床转化途径和整合服务模式。

miRNA定序和检测方法开发领域正经历着多项变革，这些变革正在重新定义技术预期和商业策略。次世代定序平台提高了灵敏度和多重分析能力，能够从少量样本同时分析数百种小RNA。这促进了纵向监测和微创取样等新应用情境的出现。同时，检测化学和样品製备技术的进步降低了偏差，并提高了定序批次间的一致性。这使得不同研究之间的比较变得越来越可行，并吸引了越来越多的临床研究项目的关注。

关税趋势的变化对 miRNA定序和检测作业的供应链策略、采购惯例和復原计画产生了哪些影响？

近期贸易政策的调整进一步增加了依赖进口设备、耗材和试剂的机构在采购计画、供应链设计和成本管理方面的复杂性。影响进口实验室设备和试剂的关税措施提高了许多市场参与企业的实际接收成本，迫使采购团队重新评估供应商关係、合约条款和库存策略。为此，一些机构正在加快供应商多元化的步伐，并从地理位置较近的製造商采购关键材料，以降低跨境政策变化带来的风险。

结合产品类型、技术、应用、工作流程、最终用户和样品类型等因素，提供全面的市场区隔洞察，为策略投资决策提供支援。

解读市场需要专注于多个细分因素，这些因素全面定义了产品设计、部署管道和使用者需求。根据产品类型，相关人员必须评估表达检测试剂盒（例如微阵列试剂盒、qRT-PCR 试剂盒和定序试剂盒），以及定序平台和从生物资讯服务到定序服务的各种服务。每类产品都需要不同的检验标准和支援模式。微阵列试剂盒和 qRT-PCR 试剂盒通常针对特定标靶和临床通量进行最佳化，而定序盒和平台则着重于广泛的检测范围和多重分析能力。提供生物资讯学和定序执行服务在弥合原始数据生成与其可操作性解读之间的鸿沟方面发挥着重要作用。

提供可操作的区域洞察，描绘美洲、欧洲、中东和非洲以及亚太地区的创新中心、监管预期和实际情况。

区域趋势对创新、临床应用和商业性驱动因素的出现地点有着显着影响，每个地区都有其独特的法规、报销机制和营运考量，这些因素共同决定了技术的采纳时间表。在美洲，学术研究中心、转化实验室和临床试验活动的集中，推动了对药物级定序平台和经验证的临床试验检验的需求。该地区的临床实验室通常需要在严格的监管要求与大型医院系统和专业诊断实验室的早期采纳之间取得平衡，这加速了从生物标记发现到临床评估的进程。

深入竞争考察整合工作流程、策略伙伴关係和检验的服务模式如何在 miRNA定序和检测市场中创造可持续的竞争优势。

miRNA定序和检测生态系统的竞争格局主要集中在透过整合的工作流程、检验的证据和广泛的服务来实现差异化。提供从优化的文库建构试剂盒到检验的生物资讯流程等端到端解决方案的仪器和试剂供应商，往往降低了临床检查室和转化研究团队的进入门槛。将定序能力与特定领域分析相结合的服务供应商，为寻求承包生物标记计画的申办者创造了极具吸引力的价值提案。同时，专业的生物资讯公司透过提供可重复的小RNA流程和可扩展的解读框架，也为市场增添了价值。

为行业领导者提供可操作且优先考虑的建议，以加快 miRNA倡议中的检测检验、供应弹性和临床整合。

为最大程度地提高 miRNA定序和检测的投资报酬率，相关领域的领导者应携手推进一系列策略行动，以提昇技术稳健性、供应链韧性和下游临床整合能力。应优先进行严格的检测检验和跨平台一致性研究，以证明其可重复性并促进临床检查室的应用。此外，还应建立透明、版本控制的生物资讯流程和全面的文檔，以支援监管申报和临床认证流程，从而完善湿实验室检验。

采用透明、多面向的调查方法，结合一手访谈、技术评估与供应链分析，得出切实可行的结论。

本分析所依据的研究整合了多种证据来源，以确保方法的严谨性和实际应用价值。研究人员对价值链上的各相关人员进行了初步的定性访谈，包括分子实验室负责人、转化研究人员、采购经理和合约研究组织（CRO）负责人。这些对话有助于更深入了解影响miRNA定序和检验方案采用决策的营运限制、验证重点和买方偏好。

一项权威的综合分析，强调检验、协作和营运准备是将 miRNA 见解转化为临床影响的途径。

总之，miRNA定序和检测技术在基础科学和临床应用交叉领域中占据着至关重要的地位。定序平台、检测化学和生物资讯学的进步共同提高了小RNA讯号的可靠性和可解释性，拓展了其在临床和研究领域的实际应用范围。然而，要最大限度地发挥miRNA生物标记的潜力，需要严格关注检测方法的检验、平台的一致性以及供应链和法规环境下的实际操作情况。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：miRNA定序与检测市场：依产品类型划分

  • 表达检测试剂盒
    • 微阵列试剂盒
    • qRT-PCR试剂盒
    • 定序盒
  • 定序平台
  • 服务
    • 生物资讯服务
    • 定序服务

第九章：miRNA定序与检测市场：依技术划分

  • 微阵列
  • 次世代定序
  • RT-qPCR

第十章：miRNA定序与检测市场：依工作流程划分

  • 消耗品
    • 试剂盒和试剂
    • 实验室设备
  • 服务
    • 数据分析服务
    • 定序服务

第十一章：按样本类型分類的 miRNA定序与检测市场

  • 血
  • 血清/血浆
  • 组织

第十二章：miRNA定序与检测市场：依应用领域划分

  • 临床诊断
  • 疾病调查
  • 药物发现

第十三章：miRNA定序与检测市场：依最终用户划分

  • 学术机构
  • 合约研究机构
  • 医院和诊断检测机构
  • 製药和生物技术

第十四章：miRNA定序与检测市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章：miRNA定序与检测市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章：miRNA定序与检测市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国miRNA定序与检测市场

第十八章：中国miRNA定序与检测市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Agilent Technologies, Inc.
  • BGI Genomics
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche Ltd
  • Guardant Health, Inc.
  • Illumina, Inc.
  • LC Sciences
  • NanoString Technologies, Inc.
  • New England Biolabs, Inc.
  • Norgen Biotek Corp.
  • PerkinElmer, Inc.
  • QIAGEN NV
  • SomaLogic, Inc.
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.
Product Code: MRR-0A609A26A984

The miRNA Sequencing & Assay Market was valued at USD 435.69 million in 2025 and is projected to grow to USD 502.41 million in 2026, with a CAGR of 14.55%, reaching USD 1,127.65 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 435.69 million
Estimated Year [2026] USD 502.41 million
Forecast Year [2032] USD 1,127.65 million
CAGR (%) 14.55%

A comprehensive introduction to contemporary miRNA sequencing and assay capabilities that frame scientific potential and translational hurdles for clinical adoption

MicroRNA sequencing and assay science has rapidly matured from a niche research capability into a core element of molecular profiling strategies across translational research and clinical development. Advances in sample processing, library preparation chemistry, and analytical pipelines have increased the reliability of small RNA detection, while parallel improvements in instrumentation have compressed turn-around times and reduced the barrier to routine implementation. As a result, stakeholders across academic institutions, contract research organizations, hospitals and diagnostic laboratories, and pharmaceutical and biotech companies now evaluate miRNA solutions not just as exploratory tools but as candidates for biomarker development, companion diagnostics, and targeted therapeutic discovery.

Despite this progress, the field contends with persistent technical challenges that shape adoption decisions. Low input abundance, sequence similarity among family members, and the presence of isomiRs require highly selective assay design and rigorous quality controls. Moreover, bioinformatics workflows that translate raw reads into actionable signatures remain a differentiator; reproducible alignment, normalization, and annotation strategies determine whether a candidate miRNA achieves translational utility. Regulatory and clinical validation pathways introduce additional complexity, underlining the importance of integrated assays that pair robust wet-lab protocols with validated computational pipelines.

Transitioning from exploratory science to clinical utility calls for coordinated investments in assay standardization, cross-laboratory reproducibility studies, and partnerships that bridge instrument vendors, kit manufacturers, and service providers. In this context, emphasis on interoperable workflows and vendor-agnostic data formats is rising, enabling researchers and clinicians to compare results across platforms and accelerate the translation of miRNA signals into diagnostic and therapeutic insights. Taken together, these dynamics position miRNA sequencing and assay capabilities as pivotal enablers of precision medicine initiatives when implemented with methodological rigor and strategic alignment to clinical goals.

Critical transformative shifts reshaping miRNA sequencing and assay workflows that enable scalable clinical translational pathways and integrated service models

The landscape of miRNA sequencing and assay development is undergoing several transformative shifts that redefine technical expectations and commercial strategies. Next generation sequencing platforms have extended sensitivity and multiplexing capacity, enabling simultaneous profiling of hundreds of small RNAs from reduced sample inputs, which in turn drives new use cases in longitudinal monitoring and minimally invasive sampling. Concurrently, improvements in assay chemistry and library preparation have reduced bias and increased uniformity across sequencing runs, making cross-study comparison increasingly feasible and fueling broader interest from clinical research programs.

At the same time, the convergence of RT-qPCR, microarray, and sequencing approaches has created a tiered diagnostics ecosystem in which high-throughput discovery via sequencing is complemented by targeted validation using qRT-PCR assays or microarray panels. This multi-modal pathway supports rigorous biomarker qualification: discovery, orthogonal validation, and then deployment in a regulated clinical testing environment. Alongside wet-lab evolution, bioinformatics and machine learning algorithms have matured to handle small-RNA specific challenges, including isomiR detection, sequence trimming artifacts, and cross-platform normalization, thereby enhancing confidence in derived signatures.

Operational shifts are also evident. Service providers are expanding offerings to include end-to-end solutions that combine sample logistics, sequencing execution, and interpretive analytics, while instrument and reagent manufacturers prioritize integrated workflows that improve ease of adoption for clinical labs. Policy and payer discourse is increasingly focused on evidentiary standards for molecular biomarkers, prompting closer collaboration among assay developers, clinical laboratories, and regulatory bodies to establish validation templates and performance benchmarks. Taken together, these shifts are moving miRNA assays from experimental workflows toward standardized components of precision medicine pipelines.

How evolving tariff dynamics have reshaped supply-chain strategy, procurement practices, and resiliency planning across miRNA sequencing and assay operations

Recent trade policy adjustments have introduced an additional layer of complexity into procurement planning, supply-chain design, and cost management for organizations that rely on imported instruments, consumables, and reagents. Tariff actions affecting imported laboratory equipment and reagents have increased the effective landed cost for many market participants, prompting procurement teams to reassess vendor relationships, contract terms, and inventory strategies. In response, some organizations have accelerated efforts to diversify suppliers and source critical inputs from geographically closer manufacturers to mitigate exposure to cross-border policy shifts.

These dynamics have material operational consequences. Research institutions and clinical laboratories are adapting purchasing cadences, increasing buffer stocks of essential reagents, and extending supplier qualification processes to include alternative domestic and regional partners. Manufacturers and distributors, for their part, are exploring localized assembly, alternative logistics routing, and restructured pricing models to preserve customer access while managing margin pressures. Service providers that operate international sequencing centers are likewise evaluating where to locate capacity and how to structure customer pricing to reflect added duty and compliance costs.

Over time, sustained tariff pressures often catalyze investment in regional manufacturing capabilities and in strategic partnerships that reduce dependency on a single supply base. At the same time, procurement professionals and R&D leaders must weigh the trade-offs between supply resilience and the technical performance of alternative components. Continuing to monitor policy developments and proactively engaging with suppliers to understand inventory pipelines, lead times, and contingency arrangements will remain essential to maintain operational continuity and protect timelines for miRNA assay development and clinical validation.

Comprehensive segmentation insights that align product types, technologies, applications, workflows, end users, and sample type considerations to inform strategic investment

Interpreting the market requires attention to multiple segmentation vectors that collectively define product design, adoption pathways, and user requirements. Based on product type, stakeholders must evaluate Expression Assay Kit options that include microarray kits, qRT-PCR kits, and sequencing kits alongside sequencing platforms and a range of services that span bioinformatics services and sequencing services. Each product class demands distinct validation standards and support models: microarray and qRT-PCR kits are often optimized for targeted panels and clinical throughput, whereas sequencing kits and platforms favor discovery breadth and multiplex capacity. Services that provide bioinformatics and sequencing execution bridge the gap between raw data generation and actionable interpretation.

Technology segmentation highlights the co-existence of microarray, next generation sequencing, and RT-qPCR approaches, each providing a different balance of throughput, sensitivity, and cost per sample. Microarray solutions remain valuable for standardized panels and comparative studies, RT-qPCR is the workhorse for targeted validation and clinical assay confirmation, and next generation sequencing delivers comprehensive discovery and isoform-level resolution that supports research and novel biomarker identification.

When viewed through the lens of application, clinical diagnostics, disease research, and drug discovery each place unique demands on assay performance, regulatory documentation, and longitudinal reproducibility. End users including academic institutions, contract research organizations, hospitals and diagnostic laboratories, and pharmaceutical and biotech companies require differentiated support: academic teams favor openness and flexible protocols for exploratory work, CROs emphasize throughput and standardized reporting, clinical labs prioritize validated kits and compliance documentation, and industry sponsors focus on integration with clinical trial workflows.

Workflow segmentation divides offerings into consumables and services, where consumables include kits and reagents as well as labware and services encompass data analysis services and sequencing services. Consumable quality and batch consistency strongly influence downstream data reliability, while services that deliver sophisticated analytics are increasingly critical to translate complex small-RNA profiles into clinically meaningful readouts. Sample type further nuances product selection and protocol design; assays optimized for blood, serum/plasma, or tissue must address distinct pre-analytical variables such as RNA yield, degradation profiles, and matrix effects. Taken together, these segmentation perspectives frame where investments in assay optimization, regulatory strategy, and customer support will deliver the greatest return in adoption and impact.

Actionable regional insights that map innovation hubs, regulatory expectations, and operational realities across the Americas, EMEA, and Asia-Pacific regions

Regional dynamics strongly influence where innovation, clinical translation, and commercial traction occur, and each geography presents distinct regulatory, reimbursement, and operational considerations that shape adoption timelines. In the Americas, a concentration of academic research centers, translational institutes, and clinical trial activity drives demand for both discovery-grade sequencing platforms and validated assays for clinical studies. Clinical laboratories in this region often balance stringent regulatory expectations with early adoption by leading hospital systems and specialist diagnostic labs, which accelerates the pathway from biomarker discovery to clinical evaluation.

Across Europe, Middle East & Africa, regulatory harmonization efforts and established reimbursement frameworks create a landscape where assay validation and clinical-grade documentation receive pronounced emphasis. Public research funding and collaborative networks in several European markets support multi-center validation studies that enhance cross-validation and reproducibility. In the Middle East and Africa, pockets of investment in advanced diagnostics and research infrastructure are emerging; however, logistical considerations and supply-chain resilience often inform procurement strategies and partnerships in these markets.

The Asia-Pacific region is notable for a mix of high-volume manufacturing capacity, growing clinical research capabilities, and rapidly expanding hospital systems that are investing in molecular diagnostics. Local manufacturing hubs support reagent and consumable supply, while a growing base of clinical sequencing centers and contract research organizations expands service availability. Regulatory frameworks across the region vary, creating heterogeneity in clinical adoption speed, yet collaborative initiatives and public-private partnerships frequently accelerate localized validation and commercialization. Understanding these regional contrasts helps organizations tailor partnerships, localization efforts, and go-to-market strategies to the operational realities and clinical priorities of each geography.

Key competitive insights into how integrated workflows, strategic partnerships, and validated service models create durable advantages in miRNA sequencing and assay markets

Competitive dynamics in the miRNA sequencing and assay ecosystem center on differentiation through integrated workflows, validation evidence, and service breadth. Instrument and reagent suppliers that offer end-to-end solutions, from optimized library kits to validated bioinformatics pipelines, tend to reduce implementation friction for clinical laboratories and translational research teams. Service providers that combine sequencing capacity with domain-specific analytics create compelling value propositions for sponsors seeking turnkey biomarker programs, while specialized bioinformatics firms add value by delivering reproducible small-RNA pipelines and scalable interpretation frameworks.

Strategic partnerships and collaborations are a prevalent route to capability expansion. Alliances between kit manufacturers and clinical laboratories, or between sequencing centers and pharmaceutical sponsors, enable co-development of assays and shared validation studies that accelerate clinical qualification. At the same time, competition for clinical and commercial customers emphasizes the need for robust customer support, training, and documentation that demonstrate assay performance and clinical utility. Intellectual property around assay chemistry and computational methods can create barriers to entry but also opportunities for licensing and white-label offerings.

Operational excellence differentiates market leaders. Firms that invest in quality management systems, regulatory affairs expertise, and transparent validation data tend to build greater trust with hospital laboratories and diagnostic networks. Additionally, companies that offer flexible commercial models, including subscription analytics, per-sample sequencing services, and bespoke panel development, appeal to a broader set of end users. Ultimately, sustained competitive advantage will accrue to organizations that combine rigorous technical validation with service models that align to clinical workflows and the reimbursement realities of diverse health systems.

Practical and prioritized recommendations for industry leaders to fast-track assay validation, supply resilience, and clinical integration for miRNA initiatives

Leaders seeking to maximize the impact of miRNA sequencing and assay investments should pursue a coordinated set of strategic actions that address technical robustness, supply-chain resilience, and downstream clinical integration. Prioritize rigorous assay validation and cross-platform concordance studies to demonstrate reproducibility and to facilitate adoption by clinical laboratories. Complement wet-lab validation with transparent, version-controlled bioinformatics pipelines and comprehensive documentation that support regulatory submissions and clinical accreditation processes.

Diversify sourcing strategies to reduce exposure to sudden tariff or logistics disruptions, while simultaneously cultivating regional manufacturing or distribution partnerships where feasible. Invest in supplier qualification processes, extended reagent inventory planning, and contractual terms that support continuity of supply. From a commercial perspective, design modular offerings that couple discovery sequencing with orthogonal validation options such as RT-qPCR panels or microarray confirmations, enabling customers to progress from research to clinical validation within a coherent framework.

Strengthen customer enablement through training programs, shared protocols, and on-site or virtual assay setup services that reduce implementation risk for laboratories. Engage early and proactively with clinical stakeholders, payers, and regulatory advisors to articulate evidence generation pathways and to de-risk reimbursement conversations. Finally, prioritize data governance, interoperability, and security to foster clinician trust and to support multi-center validation efforts. By aligning technical rigor with operational resilience and customer-centric service design, organizations can accelerate translational progress and position themselves as trusted partners in precision medicine initiatives.

A transparent, triangulated research methodology combining primary interviews, technical assessments, and supply-chain analysis to support actionable conclusions

The research underpinning this analysis combined multiple evidence streams to ensure methodological rigor and practical relevance. Primary qualitative interviews were conducted with stakeholders across the value chain, including molecular laboratory directors, translational researchers, procurement leads, and leaders of contract research organizations. These conversations informed an understanding of operational constraints, validation priorities, and buyer preferences that shape adoption decisions for miRNA sequencing and assay solutions.

Complementing primary interviews, technical assessments reviewed laboratory protocols, assay performance literature, and publicly available regulatory guidance to evaluate methodological strengths and common failure modes. Supply-chain mapping exercises traced key nodes for reagent and instrument availability, while procurement case studies illustrated how organizations adapt purchasing strategies in response to policy or logistics pressures. Competitive landscape analysis examined product portfolios, service offerings, and partnership strategies to identify common patterns of differentiation and value capture.

Data triangulation methods synthesized qualitative insights with technical evidence, enabling robust conclusions about technology trajectories and adoption levers. Wherever feasible, validation criteria emphasized reproducibility, orthogonal confirmation pathways, and the completeness of documentation that supports clinical use. The methodology focused on transparency and traceability, documenting sources and rationale for analytical judgments so that readers can assess implications for their own programs and investment decisions.

A conclusive synthesis emphasizing validation, collaboration, and operational readiness as the pathway to transform miRNA insights into clinical impact

In sum, miRNA sequencing and assay capabilities occupy a pivotal position at the intersection of discovery science and clinical translation. Advances in sequencing platforms, assay chemistries, and bioinformatics have collectively improved the fidelity and interpretability of small-RNA signals, expanding the range of viable clinical and research applications. Yet realizing the full potential of miRNA biomarkers requires disciplined attention to assay validation, cross-platform concordance, and the operational realities of supply chains and regulatory environments.

Stakeholders that align investments across technical development, regulatory engagement, and customer enablement will be best positioned to convert discovery-stage signals into clinically actionable tests and therapeutic companion diagnostics. At the same time, pragmatic supply-chain strategies and regional market understanding will prove critical as organizations navigate policy shifts and localized operational constraints. Moving forward, collaboration among instrument suppliers, kit manufacturers, service providers, and clinical partners will accelerate maturation of standardized workflows and evidence packages that support broader clinical adoption.

The path from characterization to clinical impact is iterative: rigorous validation, transparent analytics, and responsive service models create the conditions for trust among clinicians and payers. For organizations focused on precision medicine, investing in reproducible miRNA workflows and in partnerships that bridge discovery and clinical practice will yield durable benefits in biomarker development and patient care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. miRNA Sequencing & Assay Market, by Product Type

  • 8.1. Expression Assay Kit
    • 8.1.1. Microarray Kit
    • 8.1.2. Qrt-Pcr Kit
    • 8.1.3. Sequencing Kit
  • 8.2. Sequencing Platform
  • 8.3. Services
    • 8.3.1. Bioinformatics Services
    • 8.3.2. Sequencing Services

9. miRNA Sequencing & Assay Market, by Technology

  • 9.1. Microarray
  • 9.2. Next Generation Sequencing
  • 9.3. Rt-Qpcr

10. miRNA Sequencing & Assay Market, by Workflow

  • 10.1. Consumables
    • 10.1.1. Kits & Reagents
    • 10.1.2. Labware
  • 10.2. Services
    • 10.2.1. Data Analysis Services
    • 10.2.2. Sequencing Services

11. miRNA Sequencing & Assay Market, by Sample Type

  • 11.1. Blood
  • 11.2. Serum/Plasma
  • 11.3. Tissue

12. miRNA Sequencing & Assay Market, by Application

  • 12.1. Clinical Diagnostics
  • 12.2. Disease Research
  • 12.3. Drug Discovery

13. miRNA Sequencing & Assay Market, by End User

  • 13.1. Academic Institutions
  • 13.2. Contract Research Organizations
  • 13.3. Hospitals & Diagnostic Laboratories
  • 13.4. Pharmaceutical & Biotech

14. miRNA Sequencing & Assay Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. miRNA Sequencing & Assay Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. miRNA Sequencing & Assay Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States miRNA Sequencing & Assay Market

18. China miRNA Sequencing & Assay Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Agilent Technologies, Inc.
  • 19.6. BGI Genomics
  • 19.7. Bio-Rad Laboratories, Inc.
  • 19.8. F. Hoffmann-La Roche Ltd
  • 19.9. Guardant Health, Inc.
  • 19.10. Illumina, Inc.
  • 19.11. LC Sciences
  • 19.12. NanoString Technologies, Inc.
  • 19.13. New England Biolabs, Inc.
  • 19.14. Norgen Biotek Corp.
  • 19.15. PerkinElmer, Inc.
  • 19.16. QIAGEN N.V.
  • 19.17. SomaLogic, Inc.
  • 19.18. Takara Bio Inc.
  • 19.19. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL MIRNA SEQUENCING & ASSAY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY WORKFLOW, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES MIRNA SEQUENCING & ASSAY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA MIRNA SEQUENCING & ASSAY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY EXPRESSION ASSAY KIT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY EXPRESSION ASSAY KIT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY EXPRESSION ASSAY KIT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY EXPRESSION ASSAY KIT, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY MICROARRAY KIT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY MICROARRAY KIT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY MICROARRAY KIT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY QRT-PCR KIT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY QRT-PCR KIT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY QRT-PCR KIT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SEQUENCING KIT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SEQUENCING KIT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SEQUENCING KIT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SEQUENCING PLATFORM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SEQUENCING PLATFORM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SEQUENCING PLATFORM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY BIOINFORMATICS SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY BIOINFORMATICS SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY BIOINFORMATICS SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SEQUENCING SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SEQUENCING SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SEQUENCING SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY RT-QPCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY RT-QPCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY RT-QPCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY KITS & REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY KITS & REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY KITS & REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY LABWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY LABWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY LABWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY DATA ANALYSIS SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY DATA ANALYSIS SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY DATA ANALYSIS SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SEQUENCING SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SEQUENCING SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SEQUENCING SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERUM/PLASMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERUM/PLASMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERUM/PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY TISSUE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY TISSUE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY TISSUE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY DISEASE RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY DISEASE RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY DISEASE RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY PHARMACEUTICAL & BIOTECH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY PHARMACEUTICAL & BIOTECH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY PHARMACEUTICAL & BIOTECH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS MIRNA SEQUENCING & ASSAY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS MIRNA SEQUENCING & ASSAY MARKET SIZE, BY EXPRESSION ASSAY KIT, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS MIRNA SEQUENCING & ASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS MIRNA SEQUENCING & ASSAY MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS MIRNA SEQUENCING & ASSAY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS MIRNA SEQUENCING & ASSAY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY EXPRESSION ASSAY KIT, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY EXPRESSION ASSAY KIT, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY EXPRESSION ASSAY KIT, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE MIRNA SEQUENCING & ASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE MIRNA SEQUENCING & ASSAY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE MIRNA SEQUENCING & ASSAY MARKET SIZE, BY EXPRESSION ASSAY KIT, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE MIRNA SEQUENCING & ASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE MIRNA SEQUENCING & ASSAY MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE MIRNA SEQUENCING & ASSAY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE MIRNA SEQUENCING & ASSAY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST MIRNA SEQUENCING & ASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST MIRNA SEQUENCING & ASSAY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST MIRNA SEQUENCING & ASSAY MARKET SIZE, BY EXPRESSION ASSAY KIT, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST MIRNA SEQUENCING & ASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST MIRNA SEQUENCING & ASSAY MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST MIRNA SEQUENCING & ASSAY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST MIRNA SEQUENCING & ASSAY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY EXPRESSION ASSAY KIT, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC MIRNA SEQUENCING & ASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC MIRNA SEQUENCING & ASSAY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC MIRNA SEQUENCING & ASSAY MARKET SIZE, BY EXPRESSION ASSAY KIT, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC MIRNA SEQUENCING & ASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC MIRNA SEQUENCING & ASSAY MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC MIRNA SEQUENCING & ASSAY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC MIRNA SEQUENCING & ASSAY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN MIRNA SEQUENCING & ASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN MIRNA SEQUENCING & ASSAY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN MIRNA SEQUENCING & ASSAY MARKET SIZE, BY EXPRESSION ASSAY KIT, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN MIRNA SEQUENCING & ASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN MIRNA SEQUENCING & ASSAY MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN MIRNA SEQUENCING & ASSAY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN MIRNA SEQUENCING & ASSAY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. GCC MIRNA SEQUENCING & ASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. GCC MIRNA SEQUENCING & ASSAY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. GCC MIRNA SEQUENCING & ASSAY MARKET SIZE, BY EXPRESSION ASSAY KIT, 2018-2032 (USD MILLION)
  • TABLE 197. GCC MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 198. GCC MIRNA SEQUENCING & ASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 199. GCC MIRNA SEQUENCING & ASSAY MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 200. GCC MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 201. GCC MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 202. GCC MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. GCC MIRNA SEQUENCING & ASSAY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 204. GCC MIRNA SEQUENCING & ASSAY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION MIRNA SEQUENCING & ASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION MIRNA SEQUENCING & ASSAY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION MIRNA SEQUENCING & ASSAY MARKET SIZE, BY EXPRESSION ASSAY KIT, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION MIRNA SEQUENCING & ASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION MIRNA SEQUENCING & ASSAY MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION MIRNA SEQUENCING & ASSAY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION MIRNA SEQUENCING & ASSAY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS MIRNA SEQUENCING & ASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS MIRNA SEQUENCING & ASSAY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS MIRNA SEQUENCING & ASSAY MARKET SIZE, BY EXPRESSION ASSAY KIT, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS MIRNA SEQUENCING & ASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS MIRNA SEQUENCING & ASSAY MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS MIRNA SEQUENCING & ASSAY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS MIRNA SEQUENCING & ASSAY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. G7 MIRNA SEQUENCING & ASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 228. G7 MIRNA SEQUENCING & ASSAY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. G7 MIRNA SEQUENCING & ASSAY MARKET SIZE, BY EXPRESSION ASSAY KIT, 2018-2032 (USD MILLION)
  • TABLE 230. G7 MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 231. G7 MIRNA SEQUENCING & ASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 232. G7 MIRNA SEQUENCING & ASSAY MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 233. G7 MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 234. G7 MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 235. G7 MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. G7 MIRNA SEQUENCING & ASSAY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 237. G7 MIRNA SEQUENCING & ASSAY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. NATO MIRNA SEQUENCING & ASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 239. NATO MIRNA SEQUENCING & ASSAY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. NATO MIRNA SEQUENCING & ASSAY MARKET SIZE, BY EXPRESSION ASSAY KIT, 2018-2032 (USD MILLION)
  • TABLE 241. NATO MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 242. NATO MIRNA SEQUENCING & ASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 243. NATO MIRNA SEQUENCING & ASSAY MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 244. NATO MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 245. NATO MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 246. NATO MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. NATO MIRNA SEQUENCING & ASSAY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 248. NATO MIRNA SEQUENCING & ASSAY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 249. GLOBAL MIRNA SEQUENCING & ASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES MIRNA SEQUENCING & ASSAY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES MIRNA SEQUENCING & ASSAY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES MIRNA SEQUENCING & ASSAY MARKET SIZE, BY EXPRESSION ASSAY KIT, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED STATES MIRNA SEQUENCING & ASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED STATES MIRNA SEQUENCING & ASSAY MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED STATES MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED STATES MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES MIRNA SEQUENCING & ASSAY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED STATES MIRNA SEQUENCING & ASSAY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA MIRNA SEQUENCING & ASSAY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. CHINA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY EXPRESSION ASSAY KIT, 2018-2032 (USD MILLION)
  • TABLE 264. CHINA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 265. CHINA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 266. CHINA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 267. CHINA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 268. CHINA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 269. CHINA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. CHINA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 271. CHINA MIRNA SEQUENCING & ASSAY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)